NCT06161909View on ClinicalTrials.gov

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Esophageal Squamous Cell Carcinoma Thoracic Stage IIEsophageal Squamous Cell Carcinoma Thoracic Stage IIIEsophageal Squamous Cell Carcinoma Thoracic Stage IV
Interventions
DRUG

sintilimab

200mg fixed dose Q3W,1 year

Trial Locations (1)

350100

Fujian, Fujian

All Listed Sponsors
lead

Fujian Medical University Union Hospital

OTHER